Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 144 | 2.320 |
Why?
|
| Coronary Disease | 9 | 2015 | 82 | 1.680 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 57 | 1.480 |
Why?
|
| Cisplatin | 2 | 2023 | 95 | 1.430 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 427 | 1.330 |
Why?
|
| Secondary Prevention | 5 | 2020 | 67 | 1.300 |
Why?
|
| Cardiology | 5 | 2021 | 75 | 1.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 337 | 1.180 |
Why?
|
| Cardiac Rehabilitation | 4 | 2021 | 9 | 1.140 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 691 | 1.060 |
Why?
|
| Coronary Artery Disease | 4 | 2017 | 138 | 0.970 |
Why?
|
| Acute Coronary Syndrome | 4 | 2021 | 16 | 0.890 |
Why?
|
| Acrylamides | 2 | 2020 | 5 | 0.860 |
Why?
|
| Aniline Compounds | 2 | 2020 | 46 | 0.850 |
Why?
|
| Humans | 45 | 2023 | 30994 | 0.780 |
Why?
|
| Exercise Test | 3 | 2018 | 128 | 0.770 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 4 | 0.740 |
Why?
|
| Benzimidazoles | 1 | 2021 | 11 | 0.740 |
Why?
|
| Carboplatin | 1 | 2021 | 50 | 0.740 |
Why?
|
| Heart Failure | 7 | 2021 | 219 | 0.730 |
Why?
|
| Standard of Care | 1 | 2020 | 11 | 0.730 |
Why?
|
| Paclitaxel | 1 | 2021 | 76 | 0.730 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 7 | 0.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 356 | 0.670 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 19 | 0.660 |
Why?
|
| Medicine | 2 | 2008 | 11 | 0.640 |
Why?
|
| Physicians, Family | 2 | 2008 | 8 | 0.630 |
Why?
|
| Specialization | 2 | 2008 | 17 | 0.630 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 16 | 0.620 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 2 | 0.620 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.620 |
Why?
|
| Life Style | 3 | 2019 | 226 | 0.600 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 52 | 0.590 |
Why?
|
| Mutation | 1 | 2019 | 409 | 0.580 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 3 | 0.570 |
Why?
|
| Taxoids | 1 | 2017 | 14 | 0.570 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 260 | 0.560 |
Why?
|
| Apoptosis | 2 | 2022 | 260 | 0.560 |
Why?
|
| Hypertension | 2 | 2019 | 288 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 344 | 0.540 |
Why?
|
| Cell Proliferation | 1 | 2017 | 204 | 0.540 |
Why?
|
| ErbB Receptors | 3 | 2023 | 81 | 0.530 |
Why?
|
| Neoplasms | 1 | 2018 | 260 | 0.490 |
Why?
|
| Depression | 3 | 2018 | 481 | 0.490 |
Why?
|
| Aged | 20 | 2023 | 10045 | 0.480 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 31 | 0.470 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 49 | 0.460 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 161 | 0.460 |
Why?
|
| Return to Work | 1 | 2014 | 53 | 0.450 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 25 | 0.450 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 57 | 0.430 |
Why?
|
| Middle Aged | 17 | 2021 | 10192 | 0.430 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 376 | 0.430 |
Why?
|
| Male | 20 | 2023 | 16442 | 0.420 |
Why?
|
| Female | 19 | 2021 | 16980 | 0.390 |
Why?
|
| Critical Pathways | 1 | 2011 | 22 | 0.370 |
Why?
|
| Program Evaluation | 3 | 2017 | 136 | 0.370 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 30 | 0.370 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 356 | 0.340 |
Why?
|
| Chest Pain | 1 | 2009 | 24 | 0.340 |
Why?
|
| Mass Screening | 1 | 2011 | 186 | 0.340 |
Why?
|
| Risk Factors | 11 | 2019 | 2586 | 0.330 |
Why?
|
| Prognosis | 4 | 2021 | 918 | 0.330 |
Why?
|
| Australia | 8 | 2021 | 45 | 0.330 |
Why?
|
| Smartphone | 2 | 2021 | 16 | 0.330 |
Why?
|
| Models, Statistical | 1 | 2009 | 135 | 0.320 |
Why?
|
| Medication Adherence | 1 | 2009 | 73 | 0.310 |
Why?
|
| Exercise Therapy | 2 | 2021 | 113 | 0.300 |
Why?
|
| Biomarkers | 3 | 2020 | 733 | 0.290 |
Why?
|
| Young Adult | 4 | 2021 | 2063 | 0.290 |
Why?
|
| Death, Sudden | 1 | 2006 | 12 | 0.270 |
Why?
|
| Quality of Life | 4 | 2021 | 697 | 0.260 |
Why?
|
| Adult | 8 | 2021 | 8929 | 0.240 |
Why?
|
| Prospective Studies | 6 | 2018 | 1898 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 54 | 0.240 |
Why?
|
| Risk Assessment | 5 | 2019 | 718 | 0.240 |
Why?
|
| Prevalence | 2 | 2019 | 499 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 34 | 0.220 |
Why?
|
| Cetuximab | 1 | 2023 | 9 | 0.220 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 35 | 0.220 |
Why?
|
| Counseling | 2 | 2017 | 49 | 0.200 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 8 | 0.200 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 42 | 0.200 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 62 | 0.200 |
Why?
|
| Radiosurgery | 1 | 2021 | 38 | 0.190 |
Why?
|
| DDT | 1 | 2020 | 1 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 5189 | 0.180 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 6 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 192 | 0.180 |
Why?
|
| Comorbidity | 4 | 2021 | 507 | 0.170 |
Why?
|
| Proteomics | 1 | 2020 | 96 | 0.170 |
Why?
|
| United Kingdom | 1 | 2019 | 51 | 0.170 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 2 | 0.170 |
Why?
|
| Blood Circulation | 1 | 2019 | 3 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 3 | 0.170 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 60 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3656 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2020 | 191 | 0.170 |
Why?
|
| Walking Speed | 1 | 2019 | 43 | 0.170 |
Why?
|
| France | 1 | 2019 | 21 | 0.170 |
Why?
|
| Diastole | 1 | 2019 | 35 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2019 | 36 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 36 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 21 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2019 | 70 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 54 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 12 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 79 | 0.160 |
Why?
|
| Bias | 2 | 2008 | 36 | 0.160 |
Why?
|
| Mouth | 1 | 2018 | 12 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 177 | 0.160 |
Why?
|
| American Heart Association | 1 | 2018 | 30 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2019 | 98 | 0.160 |
Why?
|
| Pharynx | 1 | 2018 | 15 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3806 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 549 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2018 | 79 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 61 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 101 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 87 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 274 | 0.150 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 173 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 23 | 0.140 |
Why?
|
| Caspases | 1 | 2017 | 33 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2017 | 46 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 149 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 497 | 0.140 |
Why?
|
| Health Behavior | 3 | 2021 | 163 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 238 | 0.140 |
Why?
|
| Blotting, Western | 1 | 2017 | 178 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 507 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2019 | 2042 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2019 | 452 | 0.140 |
Why?
|
| Telephone | 2 | 2014 | 26 | 0.130 |
Why?
|
| United States | 3 | 2018 | 2375 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2016 | 158 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1009 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 217 | 0.120 |
Why?
|
| Depressive Disorder | 2 | 2015 | 192 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 43 | 0.110 |
Why?
|
| Calcium | 1 | 2017 | 502 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2013 | 144 | 0.110 |
Why?
|
| New Zealand | 3 | 2020 | 13 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2013 | 75 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 216 | 0.100 |
Why?
|
| Affect | 1 | 2011 | 66 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2009 | 41 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 7 | 0.080 |
Why?
|
| Family Practice | 1 | 2009 | 20 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 36 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 28 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 28 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 42 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 73 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 35 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 112 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 198 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 66 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2013 | 991 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 18 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2006 | 22 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 785 | 0.070 |
Why?
|
| Cholesterol | 2 | 2003 | 54 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 403 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 30 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1921 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 1672 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 8 | 0.060 |
Why?
|
| Immobilization | 1 | 2023 | 15 | 0.060 |
Why?
|
| Laryngectomy | 1 | 2023 | 22 | 0.060 |
Why?
|
| Neck | 1 | 2023 | 35 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 40 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 6 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 73 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 62 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 71 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 35 | 0.050 |
Why?
|
| Cardiovascular Agents | 2 | 2013 | 32 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 8 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 20 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 4 | 0.050 |
Why?
|
| Walk Test | 1 | 2021 | 10 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 16 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 339 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 230 | 0.050 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2020 | 11 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 43 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 429 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 164 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 305 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 164 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 298 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 112 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 23 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 286 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 89 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 145 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 159 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 176 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 139 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 817 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 167 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2017 | 21 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 36 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 511 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 499 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 148 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2017 | 320 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 226 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 80 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 13 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 126 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 873 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 120 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 662 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 321 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1133 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 156 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 194 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2013 | 12 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 24 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 52 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2013 | 78 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 23 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 44 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 67 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 243 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 23 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 47 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 69 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 118 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 154 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 12 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 62 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 79 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 147 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 324 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 341 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 213 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 307 | 0.010 |
Why?
|